Patients who are hospitalized with cirrhosis are in trouble. They may have hepatic encephalopathy leading to impaired mentation and possible coma. They may have acute kidney injury that requires a liver transplant. They may have portal hypertension leading to ascites and spontaneous bacterial peritonitis. And they may have potentially fatal variceal bleeding.
Adequate nutrition is important for growth and meeting developmental milestones for all children. But for pediatric liver patients, overnutrition or undernutrition can have devastating effects.
Andrew P. Keaveny, MD, FRCPI, FAASLD
Consultant Hepatologist and Medical Director of Liver Transplant, Mayo Clinic, Jacksonville, Florida; Associate Professor of Medicine, Mayo Clinic College of Medicine and Science; Chair, AASLD Annual Meeting Education Committee; Member of the AASLD Maintenance of Certification and Scientific Planning Committees
The management of hepatocellular cancer (HCC) saw meaningful advances in 2016 with the introduction of two compounds, regorafenib and lenvatinib, for patients with advanced HCC.
Four experts will discuss the management for nonalcoholic fatty liver disease (NAFLD) and its progression to nonalcoholic steatohepatitis (NASH) during Tuesday’s AASLD Clinical Symposium Identification and Management of Patients with NAFLD/NASH.
Six cutting-edge abstracts will be presented during Sunday afternoon’s AASLD Plenary Session, which will be moderated by AASLD President Anna S. Lok, MD, FAASLD, and AASLD Secretary Kimberly A. Brown, MD, FAASLD.
In the last decade, considerable time and resources have been devoted to hepatitis C research, leading to significant treatment breakthroughs.
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) created the Drug-Induced Liver Injury (DILI) Network to collect and analyze cases of severe liver injury caused by prescription drugs, herbal products and supplements.